肾细胞癌分子靶向治疗耐药性研究进展

doi:10.3969/j.issn.2095-1264.2024.06.08

首页 > 过刊浏览>2024年第6期 >702-706. DOI:10.3969/j.issn.2095-1264.2024.06.08

肾细胞癌分子靶向治疗耐药性研究进展
DOI:
                        10.3969/j.issn.2095-1264.2024.06.08
                    
作者:
                        
                        
                    
作者单位:哈尔滨医科大学附属第一医院 泌尿外科，黑龙江 哈尔滨，150001
作者简介:廉珂，硕士，研究方向为泌尿系肿瘤的综合诊治。
通讯作者:倪少滨，硕士，教授，主任医师，研究方向为泌尿系肿瘤的综合诊治。
中图分类号:R737.11;R979.1
基金项目:

Progress in molecular targeted therapy resistance of renal cell carcinoma

Author:

Affiliation:

Department of Urology, First Affiliated Hospital of Harbin Medical University, Harbin, 150001, Heilongjiang, China

Fund Project:

摘要

图/表

访问统计

参考文献

相似文献

引证文献

资源附件

文章评论

摘要:

近年来，肾细胞癌（RCC）的分子靶向治疗飞速发展，产生了多种靶向治疗药物，大大提高了晚期转移性RCC患者的生存率，但是由于耐药性的存在，患者往往无法获得完全缓解。因此，掌握耐药性的发生机制、克服靶向治疗的耐药性，才能提高临床治疗效果。本文就RCC分子靶向治疗的耐药机制进行讨论，以期为临床科研工作提供一定的理论依据。

Abstract:

In recent years, molecular targeted therapy for renal cell carcinoma (RCC) has developed rapidly, resulting in a variety of targeted therapies, which greatly improve the survival rate of patients with advanced metastatic renal cancer, but due to the presence of drug resistance, patients often cannot achieve complete remission. Only by grasping the mechanism of drug resistance can we overcome the drug resistance of targeted therapy and improve the therapeutic effect. In this paper, the resistance mechanism of molecular targeted therapy is discussed, which provides a theoretical basis for future clinical research work.